| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sjogren's Syndrome | 67 | 2025 | 263 | 16.100 |
Why?
|
| Lupus Erythematosus, Systemic | 127 | 2025 | 990 | 13.840 |
Why?
|
| Ribonucleoproteins | 57 | 2021 | 154 | 9.410 |
Why?
|
| Autoantigens | 66 | 2021 | 212 | 9.240 |
Why?
|
| Proteins | 30 | 2023 | 251 | 8.200 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 36 | 2019 | 166 | 6.860 |
Why?
|
| RNA, Small Cytoplasmic | 36 | 2019 | 63 | 5.500 |
Why?
|
| Autoantibodies | 52 | 2023 | 474 | 5.290 |
Why?
|
| Blotting, Western | 22 | 2024 | 510 | 5.050 |
Why?
|
| Immunoblotting | 20 | 2023 | 124 | 4.980 |
Why?
|
| Antibodies, Antinuclear | 36 | 2023 | 182 | 4.640 |
Why?
|
| Curcumin | 14 | 2021 | 69 | 4.520 |
Why?
|
| Humans | 254 | 2025 | 27968 | 3.790 |
Why?
|
| Autoimmunity | 27 | 2021 | 157 | 3.630 |
Why?
|
| Antibodies | 10 | 2024 | 124 | 3.360 |
Why?
|
| Autoimmune Diseases | 16 | 2022 | 164 | 3.270 |
Why?
|
| Genetic Predisposition to Disease | 50 | 2022 | 665 | 3.000 |
Why?
|
| Hot Temperature | 13 | 2018 | 87 | 2.970 |
Why?
|
| Salivary Glands | 11 | 2020 | 51 | 2.940 |
Why?
|
| Antigens | 14 | 2024 | 67 | 2.610 |
Why?
|
| Staining and Labeling | 10 | 2018 | 69 | 2.590 |
Why?
|
| Collodion | 18 | 2019 | 19 | 2.420 |
Why?
|
| Antibody Specificity | 15 | 2024 | 114 | 2.330 |
Why?
|
| Arthritis, Rheumatoid | 9 | 2019 | 134 | 2.270 |
Why?
|
| Aldehydes | 11 | 2012 | 55 | 2.270 |
Why?
|
| Chromosomes, Human, X | 11 | 2025 | 38 | 2.100 |
Why?
|
| Coloring Agents | 8 | 2018 | 35 | 2.090 |
Why?
|
| B-Lymphocytes | 9 | 2022 | 282 | 2.010 |
Why?
|
| Female | 107 | 2025 | 15074 | 2.000 |
Why?
|
| Animals | 77 | 2025 | 10370 | 1.990 |
Why?
|
| Polyvinyls | 10 | 2015 | 14 | 1.940 |
Why?
|
| X Chromosome Inactivation | 3 | 2025 | 5 | 1.820 |
Why?
|
| Male | 86 | 2025 | 13424 | 1.740 |
Why?
|
| Membranes, Artificial | 10 | 2015 | 26 | 1.710 |
Why?
|
| Curcuma | 5 | 2018 | 8 | 1.630 |
Why?
|
| Polymorphism, Single Nucleotide | 34 | 2022 | 546 | 1.600 |
Why?
|
| Rosaniline Dyes | 7 | 2018 | 8 | 1.550 |
Why?
|
| Klinefelter Syndrome | 4 | 2016 | 9 | 1.490 |
Why?
|
| Lipid Peroxidation | 7 | 2010 | 47 | 1.480 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 9 | 2015 | 55 | 1.480 |
Why?
|
| Immunoglobulin G | 10 | 2017 | 270 | 1.450 |
Why?
|
| Sex Chromosome Aberrations | 4 | 2017 | 16 | 1.400 |
Why?
|
| Epitopes | 20 | 2021 | 183 | 1.380 |
Why?
|
| Immunohistochemistry | 4 | 2023 | 461 | 1.290 |
Why?
|
| Acrylic Resins | 4 | 2019 | 13 | 1.270 |
Why?
|
| Toll-Like Receptor 7 | 3 | 2025 | 20 | 1.210 |
Why?
|
| Buffers | 12 | 2019 | 24 | 1.210 |
Why?
|
| Sex Characteristics | 2 | 2019 | 172 | 1.180 |
Why?
|
| Peptides | 12 | 2007 | 287 | 1.180 |
Why?
|
| Immunization | 14 | 2021 | 119 | 1.160 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 4 | 2019 | 281 | 1.160 |
Why?
|
| African Americans | 17 | 2020 | 352 | 1.150 |
Why?
|
| Gene Expression Regulation | 7 | 2019 | 632 | 1.110 |
Why?
|
| Salivary Glands, Minor | 5 | 2021 | 21 | 1.100 |
Why?
|
| Middle Aged | 38 | 2025 | 7111 | 1.100 |
Why?
|
| Arthritis | 4 | 2018 | 29 | 1.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 16 | 2017 | 256 | 1.070 |
Why?
|
| Adult | 43 | 2025 | 7703 | 1.050 |
Why?
|
| Immune Tolerance | 2 | 2022 | 49 | 1.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 5 | 2019 | 39 | 1.020 |
Why?
|
| Fluorescent Dyes | 5 | 2015 | 92 | 1.010 |
Why?
|
| Gels | 4 | 2019 | 27 | 1.000 |
Why?
|
| Fatigue | 3 | 2025 | 64 | 0.990 |
Why?
|
| Preservation, Biological | 2 | 2018 | 11 | 0.960 |
Why?
|
| Mice | 28 | 2022 | 4621 | 0.900 |
Why?
|
| Peptide Fragments | 12 | 2013 | 202 | 0.890 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2018 | 126 | 0.890 |
Why?
|
| Antioxidants | 5 | 2018 | 223 | 0.870 |
Why?
|
| Fragaria | 2 | 2021 | 4 | 0.870 |
Why?
|
| Antibodies, Monoclonal | 7 | 2021 | 329 | 0.870 |
Why?
|
| DNA | 8 | 2014 | 371 | 0.850 |
Why?
|
| Antirheumatic Agents | 4 | 2017 | 57 | 0.850 |
Why?
|
| Phosphoproteins | 4 | 2015 | 117 | 0.840 |
Why?
|
| Cytokines | 5 | 2024 | 446 | 0.840 |
Why?
|
| Isoelectric Focusing | 7 | 2019 | 15 | 0.840 |
Why?
|
| Case-Control Studies | 19 | 2025 | 719 | 0.830 |
Why?
|
| Proteome | 1 | 2023 | 77 | 0.830 |
Why?
|
| Disease Models, Animal | 13 | 2025 | 1454 | 0.810 |
Why?
|
| Fruit | 3 | 2018 | 39 | 0.790 |
Why?
|
| Phosphates | 2 | 2015 | 32 | 0.780 |
Why?
|
| Lysosomes | 2 | 2019 | 56 | 0.770 |
Why?
|
| Somatic Hypermutation, Immunoglobulin | 2 | 2021 | 16 | 0.770 |
Why?
|
| Green Chemistry Technology | 2 | 2012 | 3 | 0.770 |
Why?
|
| Biomarkers | 11 | 2023 | 756 | 0.760 |
Why?
|
| Mitochondria | 1 | 2025 | 369 | 0.750 |
Why?
|
| Monocytes | 3 | 2019 | 135 | 0.750 |
Why?
|
| Molecular Weight | 11 | 2015 | 119 | 0.750 |
Why?
|
| Spondylitis, Ankylosing | 4 | 2011 | 9 | 0.740 |
Why?
|
| Lymphocytes | 4 | 2019 | 90 | 0.740 |
Why?
|
| Dipeptidases | 3 | 2006 | 5 | 0.740 |
Why?
|
| Genome-Wide Association Study | 10 | 2023 | 234 | 0.740 |
Why?
|
| Gene Dosage | 5 | 2017 | 35 | 0.730 |
Why?
|
| Alleles | 19 | 2022 | 350 | 0.730 |
Why?
|
| Cholesterol, LDL | 1 | 2021 | 64 | 0.720 |
Why?
|
| Pedigree | 14 | 2016 | 155 | 0.720 |
Why?
|
| Chloride Channel Agonists | 1 | 2021 | 5 | 0.720 |
Why?
|
| HeLa Cells | 9 | 2018 | 208 | 0.720 |
Why?
|
| Aminophenols | 1 | 2021 | 8 | 0.710 |
Why?
|
| Antibody-Producing Cells | 2 | 2018 | 15 | 0.710 |
Why?
|
| Quinolones | 1 | 2021 | 22 | 0.710 |
Why?
|
| Indians, North American | 5 | 2020 | 520 | 0.700 |
Why?
|
| Solubility | 8 | 2018 | 73 | 0.690 |
Why?
|
| Haplotypes | 20 | 2015 | 283 | 0.690 |
Why?
|
| Cystic Fibrosis | 1 | 2021 | 32 | 0.690 |
Why?
|
| Diffusion | 7 | 2019 | 39 | 0.680 |
Why?
|
| Blood Glucose | 5 | 2021 | 309 | 0.680 |
Why?
|
| Amino Acid Sequence | 22 | 2021 | 687 | 0.670 |
Why?
|
| Detergents | 2 | 2018 | 24 | 0.670 |
Why?
|
| Rheumatoid Factor | 7 | 2019 | 28 | 0.670 |
Why?
|
| Liver Failure, Acute | 1 | 2020 | 4 | 0.660 |
Why?
|
| Liver Cirrhosis, Biliary | 2 | 2016 | 10 | 0.660 |
Why?
|
| Mosaicism | 2 | 2017 | 14 | 0.660 |
Why?
|
| Sex Chromosome Disorders of Sex Development | 2 | 2017 | 11 | 0.660 |
Why?
|
| Cocaine | 1 | 2020 | 22 | 0.660 |
Why?
|
| Virus Diseases | 4 | 2017 | 39 | 0.660 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2020 | 66 | 0.650 |
Why?
|
| Signal Transduction | 3 | 2025 | 1433 | 0.650 |
Why?
|
| Plant Extracts | 2 | 2018 | 62 | 0.640 |
Why?
|
| Dendritic Cells | 2 | 2019 | 142 | 0.640 |
Why?
|
| Keratoconjunctivitis Sicca | 1 | 2019 | 4 | 0.640 |
Why?
|
| Diet | 1 | 2021 | 231 | 0.630 |
Why?
|
| Mice, Inbred BALB C | 9 | 2015 | 274 | 0.630 |
Why?
|
| Neutrophils | 5 | 2015 | 181 | 0.620 |
Why?
|
| Lupus Nephritis | 4 | 2015 | 102 | 0.620 |
Why?
|
| Polymorphism, Genetic | 6 | 2013 | 165 | 0.620 |
Why?
|
| Genetic Linkage | 9 | 2011 | 95 | 0.620 |
Why?
|
| Molecular Sequence Data | 21 | 2013 | 1048 | 0.610 |
Why?
|
| Lipoproteins, LDL | 2 | 2016 | 36 | 0.600 |
Why?
|
| Chromosomes, Human, Pair 11 | 5 | 2010 | 34 | 0.590 |
Why?
|
| Diabetes Mellitus | 1 | 2021 | 215 | 0.590 |
Why?
|
| Alkaline Phosphatase | 2 | 2015 | 31 | 0.590 |
Why?
|
| T-Lymphocytes | 7 | 2025 | 281 | 0.580 |
Why?
|
| Neoplasms | 3 | 2020 | 803 | 0.580 |
Why?
|
| Obesity | 2 | 2021 | 667 | 0.570 |
Why?
|
| Polyethylene | 3 | 2018 | 12 | 0.560 |
Why?
|
| Pressure | 1 | 2018 | 90 | 0.560 |
Why?
|
| Genotype | 19 | 2016 | 456 | 0.560 |
Why?
|
| Cell Movement | 1 | 2019 | 365 | 0.550 |
Why?
|
| Menopause | 1 | 2017 | 29 | 0.550 |
Why?
|
| Terminology as Topic | 3 | 2025 | 55 | 0.540 |
Why?
|
| Chromosome Mapping | 7 | 2013 | 130 | 0.540 |
Why?
|
| Rheumatic Diseases | 1 | 2017 | 33 | 0.540 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2016 | 27 | 0.530 |
Why?
|
| Risk Factors | 15 | 2023 | 2078 | 0.530 |
Why?
|
| Complement C1q | 3 | 2013 | 13 | 0.530 |
Why?
|
| Sex Factors | 8 | 2025 | 465 | 0.530 |
Why?
|
| Oxidation-Reduction | 7 | 2021 | 364 | 0.520 |
Why?
|
| Thyroglobulin | 1 | 2016 | 2 | 0.510 |
Why?
|
| Thyroid Function Tests | 1 | 2016 | 13 | 0.510 |
Why?
|
| Artifacts | 2 | 2019 | 50 | 0.510 |
Why?
|
| Aged | 16 | 2025 | 5383 | 0.510 |
Why?
|
| Diagnostic Errors | 1 | 2016 | 32 | 0.500 |
Why?
|
| Spectrin | 2 | 2012 | 4 | 0.500 |
Why?
|
| Biological Therapy | 1 | 2015 | 5 | 0.490 |
Why?
|
| Dental Care for Chronically Ill | 1 | 2015 | 6 | 0.490 |
Why?
|
| Thyroid Neoplasms | 1 | 2016 | 39 | 0.490 |
Why?
|
| Cyclohexanones | 1 | 2015 | 4 | 0.490 |
Why?
|
| Membrane Proteins | 3 | 2015 | 483 | 0.490 |
Why?
|
| Synovial Membrane | 1 | 2015 | 13 | 0.490 |
Why?
|
| Intestines | 2 | 2014 | 118 | 0.490 |
Why?
|
| Living Donors | 1 | 2015 | 3 | 0.480 |
Why?
|
| Parotid Gland | 1 | 2015 | 6 | 0.480 |
Why?
|
| Antigen-Antibody Reactions | 2 | 2010 | 12 | 0.480 |
Why?
|
| Dermatoglyphics | 1 | 2015 | 1 | 0.470 |
Why?
|
| Forensic Sciences | 1 | 2015 | 2 | 0.470 |
Why?
|
| Antibodies, Immobilized | 1 | 2015 | 4 | 0.470 |
Why?
|
| Benzylidene Compounds | 1 | 2015 | 29 | 0.470 |
Why?
|
| Nephrectomy | 1 | 2015 | 48 | 0.470 |
Why?
|
| Rabbits | 11 | 2012 | 276 | 0.460 |
Why?
|
| Turner Syndrome | 2 | 2017 | 7 | 0.460 |
Why?
|
| Cattle | 10 | 2012 | 388 | 0.460 |
Why?
|
| Severity of Illness Index | 7 | 2021 | 450 | 0.460 |
Why?
|
| Aneuploidy | 2 | 2011 | 21 | 0.460 |
Why?
|
| Kidney Transplantation | 1 | 2015 | 44 | 0.460 |
Why?
|
| Optical Imaging | 1 | 2015 | 34 | 0.460 |
Why?
|
| Periodontal Diseases | 1 | 2014 | 6 | 0.450 |
Why?
|
| Kidney Failure, Chronic | 1 | 2015 | 69 | 0.450 |
Why?
|
| Fibroblasts | 1 | 2015 | 156 | 0.450 |
Why?
|
| Diagnosis, Differential | 7 | 2016 | 369 | 0.440 |
Why?
|
| Probiotics | 1 | 2014 | 18 | 0.440 |
Why?
|
| Prolidase Deficiency | 1 | 2013 | 3 | 0.440 |
Why?
|
| Self Tolerance | 1 | 2013 | 9 | 0.440 |
Why?
|
| Nanostructures | 1 | 2015 | 63 | 0.440 |
Why?
|
| Rocky Mountain Spotted Fever | 1 | 2013 | 1 | 0.440 |
Why?
|
| Sacroiliac Joint | 2 | 2012 | 4 | 0.440 |
Why?
|
| Time Factors | 10 | 2020 | 1590 | 0.440 |
Why?
|
| Inflammation Mediators | 2 | 2017 | 165 | 0.430 |
Why?
|
| Gold | 1 | 2015 | 130 | 0.430 |
Why?
|
| Receptors, CCR5 | 1 | 2013 | 4 | 0.420 |
Why?
|
| Water | 3 | 2012 | 135 | 0.420 |
Why?
|
| Mice, Inbred Strains | 1 | 2013 | 61 | 0.420 |
Why?
|
| Fetal Death | 1 | 2013 | 21 | 0.410 |
Why?
|
| Saliva | 4 | 2023 | 96 | 0.410 |
Why?
|
| Free Radicals | 4 | 2006 | 39 | 0.410 |
Why?
|
| Familial Mediterranean Fever | 1 | 2012 | 1 | 0.410 |
Why?
|
| Sacroiliitis | 1 | 2012 | 1 | 0.410 |
Why?
|
| Spondylarthropathies | 1 | 2012 | 2 | 0.410 |
Why?
|
| Osteoarthritis | 2 | 2017 | 36 | 0.410 |
Why?
|
| Behcet Syndrome | 1 | 2012 | 4 | 0.410 |
Why?
|
| Xerostomia | 2 | 2013 | 9 | 0.400 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2012 | 18 | 0.400 |
Why?
|
| Thyroid Diseases | 2 | 2006 | 9 | 0.390 |
Why?
|
| Surface Plasmon Resonance | 6 | 2012 | 37 | 0.390 |
Why?
|
| Luminescent Measurements | 2 | 2009 | 31 | 0.390 |
Why?
|
| Neutropenia | 3 | 2002 | 41 | 0.390 |
Why?
|
| Urine | 2 | 2004 | 14 | 0.390 |
Why?
|
| Cell Extracts | 4 | 2012 | 14 | 0.380 |
Why?
|
| Whipple Disease | 1 | 2011 | 2 | 0.380 |
Why?
|
| Skin Diseases, Vascular | 1 | 2011 | 3 | 0.380 |
Why?
|
| Specimen Handling | 2 | 2004 | 31 | 0.380 |
Why?
|
| Vasculitis | 1 | 2011 | 13 | 0.380 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2013 | 123 | 0.370 |
Why?
|
| Thrombocytopenia | 2 | 2002 | 113 | 0.360 |
Why?
|
| Temperature | 4 | 2021 | 213 | 0.360 |
Why?
|
| Cohort Studies | 10 | 2014 | 884 | 0.360 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2025 | 82 | 0.350 |
Why?
|
| Lupus Vulgaris | 3 | 2002 | 6 | 0.350 |
Why?
|
| Interleukins | 1 | 2011 | 112 | 0.350 |
Why?
|
| Insulin | 3 | 2021 | 315 | 0.350 |
Why?
|
| Insulin Resistance | 3 | 2017 | 173 | 0.340 |
Why?
|
| Adolescent | 12 | 2017 | 3104 | 0.340 |
Why?
|
| Hyperkalemia | 1 | 2010 | 8 | 0.340 |
Why?
|
| Phenotype | 7 | 2021 | 680 | 0.340 |
Why?
|
| Potassium | 1 | 2010 | 42 | 0.340 |
Why?
|
| Genetic Loci | 5 | 2013 | 75 | 0.330 |
Why?
|
| Beverages | 1 | 2010 | 24 | 0.330 |
Why?
|
| Immunologic Factors | 1 | 2010 | 49 | 0.330 |
Why?
|
| Immobilized Proteins | 3 | 2015 | 9 | 0.330 |
Why?
|
| Electrophoresis, Agar Gel | 3 | 2011 | 12 | 0.330 |
Why?
|
| Complement System Proteins | 1 | 2009 | 24 | 0.330 |
Why?
|
| Molecular Mimicry | 2 | 2006 | 30 | 0.320 |
Why?
|
| Cell Fractionation | 2 | 2012 | 18 | 0.320 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2006 | 27 | 0.320 |
Why?
|
| Spices | 1 | 2009 | 1 | 0.320 |
Why?
|
| Cross-Linking Reagents | 3 | 2019 | 42 | 0.320 |
Why?
|
| Filtration | 1 | 2009 | 8 | 0.320 |
Why?
|
| Tars | 1 | 2009 | 4 | 0.320 |
Why?
|
| Neoplasms, Experimental | 1 | 2009 | 58 | 0.320 |
Why?
|
| Biological Availability | 4 | 2009 | 44 | 0.320 |
Why?
|
| Herpesvirus 4, Human | 2 | 2006 | 42 | 0.320 |
Why?
|
| Cell Nucleus | 2 | 2021 | 136 | 0.320 |
Why?
|
| Serologic Tests | 3 | 2017 | 19 | 0.310 |
Why?
|
| History, 19th Century | 2 | 2024 | 36 | 0.310 |
Why?
|
| Allergens | 1 | 2009 | 10 | 0.310 |
Why?
|
| Cyclophosphamide | 2 | 2020 | 41 | 0.310 |
Why?
|
| HLA-B27 Antigen | 4 | 2001 | 5 | 0.310 |
Why?
|
| Smoke | 1 | 2009 | 37 | 0.310 |
Why?
|
| Hydrogen-Ion Concentration | 3 | 2019 | 267 | 0.310 |
Why?
|
| Cosmetics | 1 | 2008 | 3 | 0.300 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2009 | 80 | 0.300 |
Why?
|
| Protein Denaturation | 3 | 2019 | 28 | 0.300 |
Why?
|
| Sodium Dodecyl Sulfate | 4 | 2019 | 18 | 0.300 |
Why?
|
| Catalase | 1 | 2008 | 49 | 0.300 |
Why?
|
| Isotretinoin | 1 | 2007 | 2 | 0.290 |
Why?
|
| Hyaluronan Receptors | 2 | 2010 | 31 | 0.290 |
Why?
|
| Registries | 5 | 2020 | 387 | 0.290 |
Why?
|
| Interferon Regulatory Factors | 3 | 2014 | 57 | 0.290 |
Why?
|
| Glucosamine | 1 | 2007 | 6 | 0.280 |
Why?
|
| Anticarcinogenic Agents | 1 | 2007 | 16 | 0.280 |
Why?
|
| Radiography, Dental | 1 | 2007 | 6 | 0.280 |
Why?
|
| HLA-DQ Antigens | 4 | 2003 | 25 | 0.280 |
Why?
|
| Work | 1 | 2007 | 3 | 0.270 |
Why?
|
| Epitopes, B-Lymphocyte | 2 | 2012 | 24 | 0.270 |
Why?
|
| Spacecraft | 1 | 2007 | 7 | 0.270 |
Why?
|
| Superoxide Dismutase | 2 | 2004 | 71 | 0.270 |
Why?
|
| Trisomy | 2 | 2017 | 19 | 0.270 |
Why?
|
| Space Flight | 1 | 2007 | 17 | 0.270 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2007 | 64 | 0.270 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 2 | 2006 | 19 | 0.270 |
Why?
|
| Radiation Injuries | 1 | 2007 | 52 | 0.270 |
Why?
|
| Antineoplastic Agents | 2 | 2011 | 679 | 0.260 |
Why?
|
| Oxygen | 3 | 2021 | 232 | 0.260 |
Why?
|
| Prevalence | 4 | 2016 | 496 | 0.260 |
Why?
|
| Protein Binding | 8 | 2015 | 657 | 0.260 |
Why?
|
| Vesicular stomatitis Indiana virus | 4 | 1995 | 8 | 0.260 |
Why?
|
| Ethanol | 2 | 2012 | 123 | 0.260 |
Why?
|
| Protein Conformation | 6 | 2021 | 257 | 0.260 |
Why?
|
| Codon, Nonsense | 1 | 2006 | 11 | 0.260 |
Why?
|
| Hypercalcemia | 1 | 2006 | 13 | 0.260 |
Why?
|
| Antibody Formation | 7 | 2006 | 77 | 0.260 |
Why?
|
| Prostatic Neoplasms | 1 | 2009 | 277 | 0.260 |
Why?
|
| Risk Assessment | 2 | 2014 | 610 | 0.260 |
Why?
|
| Rest | 1 | 2007 | 94 | 0.250 |
Why?
|
| Trichotillomania | 1 | 2005 | 1 | 0.250 |
Why?
|
| Grooming | 1 | 2005 | 3 | 0.250 |
Why?
|
| Cyanates | 2 | 2019 | 2 | 0.250 |
Why?
|
| Transcriptome | 2 | 2021 | 214 | 0.250 |
Why?
|
| Keratins | 2 | 2019 | 10 | 0.250 |
Why?
|
| Urea | 2 | 2019 | 16 | 0.250 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2005 | 4 | 0.250 |
Why?
|
| Peptide Hydrolases | 2 | 2019 | 22 | 0.250 |
Why?
|
| Pregnancy | 4 | 2016 | 1180 | 0.250 |
Why?
|
| Biopsy | 4 | 2019 | 206 | 0.250 |
Why?
|
| Antibodies, Anti-Idiotypic | 2 | 2016 | 16 | 0.250 |
Why?
|
| Immunosuppressive Agents | 2 | 2020 | 148 | 0.250 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2017 | 604 | 0.240 |
Why?
|
| Biological Products | 2 | 2016 | 65 | 0.240 |
Why?
|
| Catheters | 1 | 2025 | 24 | 0.240 |
Why?
|
| Cross Reactions | 5 | 2015 | 72 | 0.240 |
Why?
|
| Sexism | 1 | 2025 | 9 | 0.240 |
Why?
|
| Immunization, Passive | 2 | 2015 | 20 | 0.240 |
Why?
|
| Receptor, Muscarinic M3 | 2 | 2016 | 4 | 0.240 |
Why?
|
| History, 16th Century | 1 | 2024 | 7 | 0.240 |
Why?
|
| History, 17th Century | 1 | 2024 | 7 | 0.240 |
Why?
|
| History, 15th Century | 1 | 2024 | 13 | 0.240 |
Why?
|
| History, 18th Century | 1 | 2024 | 12 | 0.240 |
Why?
|
| Amyloid beta-Peptides | 1 | 2025 | 49 | 0.240 |
Why?
|
| History, Medieval | 1 | 2024 | 20 | 0.230 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 1995 | 22 | 0.230 |
Why?
|
| Animals, Laboratory | 1 | 2004 | 7 | 0.230 |
Why?
|
| RNA, Long Noncoding | 1 | 2025 | 31 | 0.230 |
Why?
|
| Tissue Extracts | 1 | 2004 | 7 | 0.230 |
Why?
|
| Syringes | 1 | 2004 | 8 | 0.230 |
Why?
|
| MicroRNAs | 2 | 2022 | 294 | 0.230 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 2011 | 27 | 0.220 |
Why?
|
| Oxygen Consumption | 1 | 2025 | 181 | 0.220 |
Why?
|
| Immunodiffusion | 5 | 2012 | 12 | 0.220 |
Why?
|
| Carrier Proteins | 2 | 2016 | 252 | 0.220 |
Why?
|
| Mucoproteins | 1 | 2004 | 6 | 0.220 |
Why?
|
| Lymphocyte Activation | 4 | 2018 | 209 | 0.220 |
Why?
|
| Tears | 1 | 2023 | 10 | 0.220 |
Why?
|
| Urinalysis | 1 | 2004 | 11 | 0.220 |
Why?
|
| Ribonucleoproteins, Small Nuclear | 7 | 2006 | 41 | 0.220 |
Why?
|
| Chromosomes, Human, Y | 2 | 2016 | 9 | 0.220 |
Why?
|
| Energy Metabolism | 1 | 2025 | 199 | 0.210 |
Why?
|
| Cost-Benefit Analysis | 1 | 2004 | 112 | 0.210 |
Why?
|
| Cross-Sectional Studies | 4 | 2020 | 957 | 0.210 |
Why?
|
| Hemoglobins | 1 | 2004 | 118 | 0.210 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2016 | 75 | 0.210 |
Why?
|
| Viral Core Proteins | 2 | 1995 | 8 | 0.210 |
Why?
|
| Capsid | 2 | 1995 | 12 | 0.210 |
Why?
|
| Administration, Oral | 3 | 2009 | 188 | 0.210 |
Why?
|
| Cross-Over Studies | 2 | 2021 | 134 | 0.210 |
Why?
|
| Sex Distribution | 2 | 2016 | 78 | 0.210 |
Why?
|
| Calcium | 1 | 2004 | 235 | 0.210 |
Why?
|
| Child | 6 | 2022 | 2225 | 0.210 |
Why?
|
| Mass Spectrometry | 2 | 2001 | 190 | 0.210 |
Why?
|
| United States | 8 | 2014 | 2139 | 0.210 |
Why?
|
| Clinical Trials as Topic | 3 | 2016 | 214 | 0.210 |
Why?
|
| Disease Progression | 2 | 2016 | 472 | 0.210 |
Why?
|
| Gene Frequency | 5 | 2016 | 185 | 0.210 |
Why?
|
| Reproducibility of Results | 3 | 2017 | 769 | 0.200 |
Why?
|
| Alzheimer Disease | 1 | 2025 | 220 | 0.200 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2021 | 77 | 0.200 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2022 | 9 | 0.200 |
Why?
|
| Chromatography, Affinity | 3 | 2015 | 32 | 0.200 |
Why?
|
| Genes, X-Linked | 1 | 2022 | 2 | 0.200 |
Why?
|
| Vitamin D Deficiency | 2 | 2014 | 31 | 0.200 |
Why?
|
| Bayes Theorem | 3 | 2017 | 100 | 0.200 |
Why?
|
| Blood Pressure | 2 | 2021 | 354 | 0.200 |
Why?
|
| Quantum Dots | 2 | 2015 | 6 | 0.200 |
Why?
|
| Proteomics | 1 | 2023 | 180 | 0.190 |
Why?
|
| Disease Susceptibility | 1 | 2022 | 74 | 0.190 |
Why?
|
| Hyperparathyroidism | 1 | 2001 | 9 | 0.190 |
Why?
|
| Limit of Detection | 2 | 2012 | 25 | 0.190 |
Why?
|
| Immunity, Innate | 2 | 2015 | 226 | 0.190 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2021 | 17 | 0.190 |
Why?
|
| c-Mer Tyrosine Kinase | 1 | 2021 | 13 | 0.190 |
Why?
|
| Trypsin | 1 | 2001 | 24 | 0.190 |
Why?
|
| Viruses | 1 | 2001 | 19 | 0.190 |
Why?
|
| DNA Methylation | 2 | 2014 | 151 | 0.190 |
Why?
|
| Symptom Assessment | 1 | 2021 | 15 | 0.180 |
Why?
|
| Liver Diseases | 1 | 2002 | 52 | 0.180 |
Why?
|
| Adipokines | 1 | 2021 | 9 | 0.180 |
Why?
|
| Epitope Mapping | 3 | 2021 | 38 | 0.180 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2021 | 6 | 0.180 |
Why?
|
| Treatment Outcome | 4 | 2020 | 2367 | 0.180 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2021 | 94 | 0.180 |
Why?
|
| Menopause, Premature | 1 | 2020 | 3 | 0.180 |
Why?
|
| Primary Ovarian Insufficiency | 1 | 2020 | 6 | 0.180 |
Why?
|
| Oklahoma | 3 | 2020 | 993 | 0.180 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2021 | 21 | 0.180 |
Why?
|
| C-Reactive Protein | 1 | 2021 | 92 | 0.180 |
Why?
|
| Linkage Disequilibrium | 7 | 2016 | 108 | 0.180 |
Why?
|
| Receptors, Androgen | 2 | 2011 | 26 | 0.170 |
Why?
|
| Gene Regulatory Networks | 1 | 2021 | 76 | 0.170 |
Why?
|
| Methyl-CpG-Binding Protein 2 | 2 | 2012 | 16 | 0.170 |
Why?
|
| Predictive Value of Tests | 3 | 2017 | 474 | 0.170 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2021 | 64 | 0.170 |
Why?
|
| In Vitro Techniques | 4 | 2017 | 241 | 0.170 |
Why?
|
| Ovary | 1 | 2020 | 69 | 0.170 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2021 | 180 | 0.170 |
Why?
|
| Cell Communication | 1 | 2021 | 67 | 0.170 |
Why?
|
| Bacterial Proteins | 2 | 1995 | 484 | 0.170 |
Why?
|
| Genetic Markers | 5 | 2012 | 93 | 0.170 |
Why?
|
| Antigens, Surface | 1 | 2000 | 39 | 0.170 |
Why?
|
| Antigens, Nuclear | 3 | 2013 | 22 | 0.170 |
Why?
|
| Immunoprecipitation | 2 | 2017 | 68 | 0.170 |
Why?
|
| STAT1 Transcription Factor | 3 | 2015 | 38 | 0.170 |
Why?
|
| Reference Standards | 2 | 2012 | 57 | 0.160 |
Why?
|
| Antigens, Neoplasm | 2 | 2011 | 56 | 0.160 |
Why?
|
| Sodium Hydroxide | 2 | 2012 | 9 | 0.160 |
Why?
|
| Calcium-Binding Proteins | 1 | 2000 | 61 | 0.160 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2017 | 329 | 0.160 |
Why?
|
| STAT4 Transcription Factor | 2 | 2009 | 23 | 0.160 |
Why?
|
| Histological Techniques | 1 | 2019 | 8 | 0.160 |
Why?
|
| Quantitative Trait Loci | 2 | 2017 | 55 | 0.160 |
Why?
|
| Solvents | 2 | 2012 | 40 | 0.160 |
Why?
|
| Protein Aggregates | 1 | 2019 | 3 | 0.160 |
Why?
|
| Epithelial Cells | 1 | 2021 | 247 | 0.160 |
Why?
|
| Polymerization | 1 | 2019 | 14 | 0.160 |
Why?
|
| Interferons | 1 | 2019 | 69 | 0.150 |
Why?
|
| Nerve Tissue Proteins | 2 | 2017 | 152 | 0.150 |
Why?
|
| Serum Albumin, Bovine | 2 | 2012 | 22 | 0.150 |
Why?
|
| Proteolysis | 1 | 2019 | 57 | 0.150 |
Why?
|
| Oligopeptides | 3 | 1998 | 96 | 0.150 |
Why?
|
| CREST Syndrome | 1 | 1998 | 1 | 0.150 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 452 | 0.150 |
Why?
|
| Blood Viscosity | 1 | 1998 | 12 | 0.150 |
Why?
|
| Transcription Factors | 2 | 2014 | 520 | 0.150 |
Why?
|
| X Chromosome | 1 | 2018 | 6 | 0.150 |
Why?
|
| Glycosylation | 1 | 2018 | 70 | 0.150 |
Why?
|
| Child, Preschool | 3 | 2012 | 1133 | 0.150 |
Why?
|
| Octoxynol | 1 | 2018 | 9 | 0.150 |
Why?
|
| Centromere | 1 | 1998 | 39 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 2 | 2016 | 242 | 0.150 |
Why?
|
| Polysorbates | 1 | 2018 | 6 | 0.140 |
Why?
|
| Infant, Newborn | 3 | 2016 | 867 | 0.140 |
Why?
|
| Promoter Regions, Genetic | 3 | 2014 | 343 | 0.140 |
Why?
|
| Protein Stability | 1 | 2018 | 43 | 0.140 |
Why?
|
| Karyotype | 1 | 2017 | 3 | 0.140 |
Why?
|
| Vaccinium macrocarpon | 1 | 2017 | 1 | 0.140 |
Why?
|
| Zinc Finger Protein Gli3 | 1 | 2017 | 2 | 0.140 |
Why?
|
| Pallister-Hall Syndrome | 1 | 2017 | 2 | 0.140 |
Why?
|
| Binding Sites, Antibody | 4 | 2000 | 14 | 0.140 |
Why?
|
| Frameshift Mutation | 1 | 2017 | 14 | 0.140 |
Why?
|
| Functional Food | 1 | 2017 | 5 | 0.140 |
Why?
|
| Arthralgia | 1 | 2017 | 7 | 0.140 |
Why?
|
| Algorithms | 2 | 2019 | 430 | 0.140 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 1 | 2017 | 6 | 0.140 |
Why?
|
| Abdominal Muscles | 1 | 2017 | 7 | 0.140 |
Why?
|
| 2',5'-Oligoadenylate Synthetase | 1 | 2017 | 9 | 0.140 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2017 | 9 | 0.140 |
Why?
|
| Postural Orthostatic Tachycardia Syndrome | 1 | 2017 | 9 | 0.140 |
Why?
|
| Protein Structure, Secondary | 2 | 2021 | 130 | 0.140 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2017 | 23 | 0.140 |
Why?
|
| Receptors, Adrenergic, beta-1 | 1 | 2017 | 22 | 0.140 |
Why?
|
| Osteoarthritis, Knee | 1 | 2017 | 25 | 0.140 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 2 | 2012 | 50 | 0.140 |
Why?
|
| False Negative Reactions | 1 | 2017 | 24 | 0.140 |
Why?
|
| Homozygote | 3 | 2022 | 36 | 0.140 |
Why?
|
| DNA-Binding Proteins | 4 | 2014 | 490 | 0.140 |
Why?
|
| Diseases in Twins | 1 | 1997 | 4 | 0.140 |
Why?
|
| Aged, 80 and over | 5 | 2014 | 2015 | 0.140 |
Why?
|
| Interferon Type I | 1 | 2017 | 56 | 0.130 |
Why?
|
| Polymyositis | 1 | 1996 | 25 | 0.130 |
Why?
|
| Exercise | 1 | 2021 | 478 | 0.130 |
Why?
|
| Genetic Association Studies | 5 | 2017 | 112 | 0.130 |
Why?
|
| Spectrophotometry, Ultraviolet | 2 | 2007 | 54 | 0.130 |
Why?
|
| Scleroderma, Systemic | 1 | 1996 | 29 | 0.130 |
Why?
|
| Heart Block | 1 | 2016 | 43 | 0.130 |
Why?
|
| Peptides, Cyclic | 1 | 2016 | 30 | 0.130 |
Why?
|
| Dietary Supplements | 2 | 2010 | 240 | 0.130 |
Why?
|
| Nicotinamide-Nucleotide Adenylyltransferase | 1 | 2016 | 4 | 0.130 |
Why?
|
| Odds Ratio | 5 | 2021 | 236 | 0.130 |
Why?
|
| Adipose Tissue | 1 | 2017 | 183 | 0.130 |
Why?
|
| Glucose | 1 | 2017 | 204 | 0.130 |
Why?
|
| Sarcoidosis | 1 | 2016 | 38 | 0.130 |
Why?
|
| Research | 1 | 2016 | 91 | 0.120 |
Why?
|
| Base Sequence | 4 | 2012 | 582 | 0.120 |
Why?
|
| Apoptosis | 3 | 2021 | 772 | 0.120 |
Why?
|
| Family Health | 3 | 2006 | 71 | 0.120 |
Why?
|
| DNA Mutational Analysis | 3 | 2017 | 94 | 0.120 |
Why?
|
| Transformation, Bacterial | 1 | 1995 | 13 | 0.120 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2015 | 5 | 0.120 |
Why?
|
| Leptin | 1 | 2015 | 67 | 0.120 |
Why?
|
| Luminescent Agents | 1 | 2015 | 3 | 0.120 |
Why?
|
| Calorimetry | 1 | 2015 | 12 | 0.120 |
Why?
|
| Tetrazolium Salts | 1 | 2015 | 9 | 0.120 |
Why?
|
| Miniaturization | 1 | 2015 | 10 | 0.120 |
Why?
|
| Submandibular Gland | 1 | 2015 | 11 | 0.120 |
Why?
|
| Sequence Analysis | 1 | 2015 | 14 | 0.120 |
Why?
|
| Centrifugation | 1 | 2015 | 7 | 0.120 |
Why?
|
| Lip | 1 | 2014 | 10 | 0.120 |
Why?
|
| snRNP Core Proteins | 6 | 2006 | 33 | 0.120 |
Why?
|
| Sialadenitis | 1 | 2015 | 16 | 0.120 |
Why?
|
| Viral Proteins | 2 | 1993 | 63 | 0.120 |
Why?
|
| Cell Proliferation | 1 | 2018 | 802 | 0.120 |
Why?
|
| Genetic Variation | 3 | 2014 | 241 | 0.120 |
Why?
|
| Receptors, Complement 3d | 1 | 2014 | 7 | 0.120 |
Why?
|
| beta Karyopherins | 1 | 2014 | 13 | 0.120 |
Why?
|
| Polyethylene Glycols | 1 | 1995 | 100 | 0.110 |
Why?
|
| Thyroiditis, Autoimmune | 2 | 2005 | 5 | 0.110 |
Why?
|
| Immunity | 1 | 2014 | 26 | 0.110 |
Why?
|
| Histones | 2 | 2022 | 92 | 0.110 |
Why?
|
| Mice, SCID | 1 | 1994 | 60 | 0.110 |
Why?
|
| Amish | 1 | 2013 | 3 | 0.110 |
Why?
|
| Oxidative Stress | 3 | 2008 | 667 | 0.110 |
Why?
|
| Indoles | 1 | 2015 | 99 | 0.110 |
Why?
|
| Metacarpophalangeal Joint | 1 | 2013 | 5 | 0.110 |
Why?
|
| ets-Domain Protein Elk-1 | 1 | 2013 | 13 | 0.110 |
Why?
|
| Enterobacteriaceae | 1 | 1993 | 8 | 0.110 |
Why?
|
| Doxycycline | 1 | 2013 | 19 | 0.110 |
Why?
|
| src-Family Kinases | 1 | 2014 | 71 | 0.110 |
Why?
|
| Sequence Analysis, DNA | 2 | 2012 | 369 | 0.110 |
Why?
|
| Prodromal Symptoms | 1 | 2013 | 1 | 0.110 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2013 | 14 | 0.110 |
Why?
|
| Freund's Adjuvant | 1 | 2013 | 8 | 0.110 |
Why?
|
| OX40 Ligand | 1 | 2013 | 16 | 0.110 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2013 | 13 | 0.110 |
Why?
|
| Carbachol | 1 | 2013 | 18 | 0.110 |
Why?
|
| Family | 3 | 2017 | 98 | 0.110 |
Why?
|
| H-2 Antigens | 1 | 2013 | 14 | 0.110 |
Why?
|
| Lymphocyte Subsets | 1 | 2013 | 8 | 0.110 |
Why?
|
| Colombia | 1 | 2013 | 9 | 0.110 |
Why?
|
| Salivation | 1 | 2013 | 11 | 0.110 |
Why?
|
| Muscle, Smooth | 1 | 2013 | 40 | 0.110 |
Why?
|
| Adaptive Immunity | 1 | 2013 | 38 | 0.110 |
Why?
|
| Chromatography, High Pressure Liquid | 4 | 2005 | 129 | 0.110 |
Why?
|
| Recombinant Proteins | 4 | 2021 | 412 | 0.100 |
Why?
|
| Nuclear Proteins | 2 | 2011 | 247 | 0.100 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2014 | 106 | 0.100 |
Why?
|
| Interleukin-10 | 1 | 2013 | 71 | 0.100 |
Why?
|
| Siblings | 1 | 2013 | 23 | 0.100 |
Why?
|
| Binding, Competitive | 1 | 2012 | 62 | 0.100 |
Why?
|
| Indians, South American | 1 | 2012 | 12 | 0.100 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2013 | 26 | 0.100 |
Why?
|
| Vitamin B 12 | 1 | 2012 | 6 | 0.100 |
Why?
|
| Precipitin Tests | 3 | 1998 | 47 | 0.100 |
Why?
|
| Smoking | 1 | 2017 | 473 | 0.100 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2012 | 14 | 0.100 |
Why?
|
| Young Adult | 6 | 2017 | 2714 | 0.100 |
Why?
|
| Urinary Bladder | 1 | 2013 | 119 | 0.100 |
Why?
|
| HEK293 Cells | 3 | 2021 | 186 | 0.100 |
Why?
|
| Escherichia coli | 1 | 1995 | 337 | 0.100 |
Why?
|
| Tularemia | 1 | 1992 | 5 | 0.100 |
Why?
|
| Prognosis | 3 | 2021 | 802 | 0.100 |
Why?
|
| Ikaros Transcription Factor | 1 | 2012 | 9 | 0.100 |
Why?
|
| Egg Proteins | 1 | 2012 | 17 | 0.100 |
Why?
|
| Transcription, Genetic | 1 | 2014 | 403 | 0.100 |
Why?
|
| Asian Americans | 4 | 2013 | 40 | 0.100 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2012 | 15 | 0.100 |
Why?
|
| Silver Nitrate | 1 | 2012 | 2 | 0.100 |
Why?
|
| TNF Receptor-Associated Factor 6 | 1 | 2012 | 6 | 0.100 |
Why?
|
| Chemical Precipitation | 1 | 2012 | 6 | 0.100 |
Why?
|
| Acetone | 1 | 2012 | 6 | 0.100 |
Why?
|
| Glyceraldehyde 3-Phosphate Dehydrogenase (NADP+) | 1 | 2011 | 3 | 0.100 |
Why?
|
| Dimethyl Sulfoxide | 1 | 2012 | 11 | 0.100 |
Why?
|
| Sex-Determining Region Y Protein | 1 | 2011 | 5 | 0.100 |
Why?
|
| Epistasis, Genetic | 1 | 2012 | 24 | 0.100 |
Why?
|
| Aquaporin 4 | 1 | 2011 | 3 | 0.100 |
Why?
|
| Infliximab | 1 | 2011 | 10 | 0.100 |
Why?
|
| Molecular Motor Proteins | 1 | 2011 | 13 | 0.100 |
Why?
|
| Point Mutation | 1 | 2012 | 60 | 0.100 |
Why?
|
| Apolipoproteins | 1 | 2011 | 21 | 0.100 |
Why?
|
| Neuromyelitis Optica | 1 | 2011 | 7 | 0.090 |
Why?
|
| Myosin Heavy Chains | 1 | 2011 | 23 | 0.090 |
Why?
|
| Cell Adhesion Molecules | 1 | 2012 | 66 | 0.090 |
Why?
|
| Protein Phosphatase 2 | 1 | 2011 | 11 | 0.090 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2012 | 163 | 0.090 |
Why?
|
| Lipoproteins, HDL | 1 | 2011 | 41 | 0.090 |
Why?
|
| Delphi Technique | 2 | 2025 | 19 | 0.090 |
Why?
|
| Sodium Chloride | 1 | 2012 | 65 | 0.090 |
Why?
|
| Organometallic Compounds | 1 | 2012 | 41 | 0.090 |
Why?
|
| Complement Factor H | 1 | 2011 | 14 | 0.090 |
Why?
|
| Pneumonia | 1 | 1992 | 89 | 0.090 |
Why?
|
| Blood Vessels | 1 | 2011 | 59 | 0.090 |
Why?
|
| Microscopy, Fluorescence | 2 | 2005 | 163 | 0.090 |
Why?
|
| Amino Sugars | 1 | 2011 | 2 | 0.090 |
Why?
|
| Exodeoxyribonucleases | 1 | 2011 | 6 | 0.090 |
Why?
|
| Intercalating Agents | 1 | 2011 | 2 | 0.090 |
Why?
|
| Malondialdehyde | 2 | 2017 | 7 | 0.090 |
Why?
|
| Pyruvate Dehydrogenase Complex | 1 | 2010 | 19 | 0.090 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2009 | 233 | 0.090 |
Why?
|
| Bacteria | 2 | 2015 | 278 | 0.090 |
Why?
|
| Indicators and Reagents | 1 | 2010 | 26 | 0.090 |
Why?
|
| Plasmids | 2 | 2005 | 126 | 0.090 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2011 | 247 | 0.090 |
Why?
|
| Methanol | 1 | 2010 | 14 | 0.080 |
Why?
|
| Equipment Design | 1 | 2011 | 217 | 0.080 |
Why?
|
| Chemokines | 1 | 2010 | 74 | 0.080 |
Why?
|
| Complement C2 | 1 | 2009 | 1 | 0.080 |
Why?
|
| Aging | 1 | 2017 | 968 | 0.080 |
Why?
|
| Complement C4 | 1 | 2009 | 16 | 0.080 |
Why?
|
| Kinetics | 2 | 2002 | 544 | 0.080 |
Why?
|
| Logistic Models | 3 | 2017 | 407 | 0.080 |
Why?
|
| Complement C3 | 1 | 2009 | 21 | 0.080 |
Why?
|
| Mice, Knockout | 2 | 2021 | 836 | 0.080 |
Why?
|
| Spectrophotometry | 1 | 2009 | 34 | 0.080 |
Why?
|
| Spliceosomes | 2 | 2002 | 11 | 0.080 |
Why?
|
| History, 20th Century | 1 | 2009 | 84 | 0.080 |
Why?
|
| Ultrafiltration | 1 | 2009 | 3 | 0.080 |
Why?
|
| CD40 Ligand | 1 | 2009 | 13 | 0.080 |
Why?
|
| Biotechnology | 1 | 2009 | 16 | 0.080 |
Why?
|
| Glucose Tolerance Test | 1 | 2009 | 59 | 0.080 |
Why?
|
| Gases | 1 | 2009 | 23 | 0.080 |
Why?
|
| Glycoproteins | 2 | 2009 | 122 | 0.080 |
Why?
|
| Immunotherapy | 1 | 2011 | 159 | 0.080 |
Why?
|
| Hysterectomy | 1 | 2009 | 85 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 520 | 0.080 |
Why?
|
| Protein Array Analysis | 1 | 2009 | 18 | 0.080 |
Why?
|
| Potassium Channels | 1 | 2009 | 20 | 0.080 |
Why?
|
| Tissue Distribution | 1 | 2009 | 136 | 0.080 |
Why?
|
| Sequence Analysis, Protein | 1 | 2009 | 15 | 0.080 |
Why?
|
| Inhalation Exposure | 1 | 2008 | 15 | 0.080 |
Why?
|
| Nerve Degeneration | 1 | 2008 | 23 | 0.080 |
Why?
|
| Air Pollutants | 1 | 2008 | 17 | 0.080 |
Why?
|
| Karyotyping | 1 | 2008 | 25 | 0.070 |
Why?
|
| Erythrocyte Membrane | 1 | 2008 | 23 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2011 | 225 | 0.070 |
Why?
|
| Polysaccharides | 1 | 2009 | 61 | 0.070 |
Why?
|
| Tooth Diseases | 1 | 2008 | 4 | 0.070 |
Why?
|
| Salivary Proteins and Peptides | 1 | 2008 | 6 | 0.070 |
Why?
|
| Rats | 2 | 2025 | 1570 | 0.070 |
Why?
|
| Inflammation | 2 | 2013 | 629 | 0.070 |
Why?
|
| Ultraviolet Rays | 2 | 2021 | 40 | 0.070 |
Why?
|
| Feces | 1 | 2009 | 109 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2012 | 817 | 0.070 |
Why?
|
| Biomarkers, Tumor | 1 | 2011 | 404 | 0.070 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2007 | 5 | 0.070 |
Why?
|
| Hyperandrogenism | 1 | 2007 | 11 | 0.070 |
Why?
|
| Amenorrhea | 1 | 2007 | 5 | 0.070 |
Why?
|
| Hirsutism | 1 | 2007 | 17 | 0.070 |
Why?
|
| Acne Vulgaris | 1 | 2007 | 6 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2021 | 112 | 0.070 |
Why?
|
| Luteinizing Hormone | 1 | 2007 | 57 | 0.070 |
Why?
|
| Immunoglobulin M | 2 | 1998 | 28 | 0.070 |
Why?
|
| Flow Cytometry | 2 | 2000 | 287 | 0.070 |
Why?
|
| Age Factors | 2 | 2017 | 733 | 0.070 |
Why?
|
| Cinnamomum aromaticum | 1 | 2007 | 2 | 0.070 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2007 | 71 | 0.070 |
Why?
|
| Multivariate Analysis | 2 | 2021 | 302 | 0.070 |
Why?
|
| Phytotherapy | 1 | 2007 | 22 | 0.070 |
Why?
|
| HLA Antigens | 2 | 2007 | 61 | 0.070 |
Why?
|
| Testosterone | 1 | 2007 | 72 | 0.070 |
Why?
|
| Internationality | 1 | 2007 | 31 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 2 | 2021 | 1561 | 0.070 |
Why?
|
| Radiation Dosage | 1 | 2007 | 53 | 0.070 |
Why?
|
| Triglycerides | 1 | 2007 | 121 | 0.070 |
Why?
|
| Rhizome | 1 | 2006 | 3 | 0.070 |
Why?
|
| Cell Line | 1 | 2009 | 695 | 0.070 |
Why?
|
| Arteries | 1 | 2007 | 65 | 0.070 |
Why?
|
| Seizures | 1 | 2007 | 48 | 0.070 |
Why?
|
| Virus Latency | 1 | 2006 | 9 | 0.070 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 1999 | 132 | 0.070 |
Why?
|
| Viral Load | 1 | 2006 | 31 | 0.070 |
Why?
|
| Milk Hypersensitivity | 1 | 2006 | 1 | 0.070 |
Why?
|
| Reactive Oxygen Species | 1 | 2008 | 284 | 0.070 |
Why?
|
| Nonprescription Drugs | 1 | 2006 | 7 | 0.070 |
Why?
|
| Glycation End Products, Advanced | 1 | 2006 | 16 | 0.060 |
Why?
|
| Calcium Carbonate | 1 | 2006 | 6 | 0.060 |
Why?
|
| Hepatomegaly | 1 | 2006 | 2 | 0.060 |
Why?
|
| Electrophoresis | 1 | 2006 | 13 | 0.060 |
Why?
|
| RNA | 2 | 2021 | 109 | 0.060 |
Why?
|
| Homeostasis | 1 | 2007 | 117 | 0.060 |
Why?
|
| Skin Ulcer | 1 | 2006 | 3 | 0.060 |
Why?
|
| Splenomegaly | 1 | 2006 | 10 | 0.060 |
Why?
|
| Biotinylation | 1 | 2006 | 19 | 0.060 |
Why?
|
| Parathyroid Hormone | 1 | 2006 | 24 | 0.060 |
Why?
|
| Alopecia | 1 | 2005 | 6 | 0.060 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2005 | 15 | 0.060 |
Why?
|
| Abnormalities, Multiple | 1 | 2006 | 35 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2005 | 10 | 0.060 |
Why?
|
| Chromatography, Thin Layer | 1 | 2005 | 18 | 0.060 |
Why?
|
| Proline | 1 | 2005 | 11 | 0.060 |
Why?
|
| Lod Score | 2 | 2002 | 36 | 0.060 |
Why?
|
| Dipeptides | 1 | 2005 | 22 | 0.060 |
Why?
|
| Cholesterol | 1 | 2007 | 200 | 0.060 |
Why?
|
| Immunophenotyping | 1 | 2005 | 60 | 0.060 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2005 | 17 | 0.060 |
Why?
|
| Heterozygote | 1 | 2005 | 65 | 0.060 |
Why?
|
| Electrophoresis, Capillary | 1 | 2005 | 13 | 0.060 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2005 | 64 | 0.060 |
Why?
|
| Models, Psychological | 1 | 2005 | 81 | 0.060 |
Why?
|
| Immune Sera | 1 | 2005 | 22 | 0.060 |
Why?
|
| Hemocyanins | 1 | 2005 | 7 | 0.060 |
Why?
|
| Membrane Glycoproteins | 2 | 2011 | 144 | 0.060 |
Why?
|
| Exercise Therapy | 2 | 2016 | 82 | 0.060 |
Why?
|
| Animal Welfare | 1 | 2004 | 4 | 0.060 |
Why?
|
| Animal Husbandry | 1 | 2004 | 9 | 0.060 |
Why?
|
| Colorimetry | 1 | 2004 | 15 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2009 | 2541 | 0.060 |
Why?
|
| Cytochromes c | 1 | 2004 | 13 | 0.060 |
Why?
|
| Subcellular Fractions | 1 | 2004 | 20 | 0.060 |
Why?
|
| Models, Genetic | 2 | 2002 | 125 | 0.060 |
Why?
|
| Superoxide Dismutase-1 | 1 | 2004 | 51 | 0.060 |
Why?
|
| Diatomaceous Earth | 1 | 2004 | 2 | 0.060 |
Why?
|
| Uromodulin | 1 | 2004 | 6 | 0.060 |
Why?
|
| Body Mass Index | 2 | 2017 | 397 | 0.060 |
Why?
|
| Major Histocompatibility Complex | 1 | 2004 | 28 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2016 | 133 | 0.050 |
Why?
|
| Causality | 1 | 2023 | 13 | 0.050 |
Why?
|
| American Native Continental Ancestry Group | 2 | 2016 | 22 | 0.050 |
Why?
|
| Thiobarbituric Acid Reactive Substances | 1 | 2003 | 5 | 0.050 |
Why?
|
| Lipid Peroxides | 1 | 2003 | 6 | 0.050 |
Why?
|
| Antigen Presentation | 2 | 2011 | 78 | 0.050 |
Why?
|
| Mutation | 2 | 2011 | 843 | 0.050 |
Why?
|
| Vimentin | 1 | 2023 | 27 | 0.050 |
Why?
|
| Mice, Inbred DBA | 1 | 2002 | 30 | 0.050 |
Why?
|
| Quality of Life | 2 | 2017 | 484 | 0.050 |
Why?
|
| Tandem Repeat Sequences | 1 | 2002 | 4 | 0.050 |
Why?
|
| Pregnancy Complications | 1 | 2004 | 111 | 0.050 |
Why?
|
| Spermine | 1 | 2022 | 3 | 0.050 |
Why?
|
| Models, Immunological | 1 | 2002 | 22 | 0.050 |
Why?
|
| Genomics | 1 | 2023 | 122 | 0.050 |
Why?
|
| Vitamin D | 2 | 2014 | 49 | 0.050 |
Why?
|
| Introns | 2 | 2013 | 42 | 0.050 |
Why?
|
| Anemia, Hemolytic | 1 | 2002 | 22 | 0.050 |
Why?
|
| Species Specificity | 1 | 2002 | 191 | 0.050 |
Why?
|
| Acetyltransferases | 1 | 2022 | 36 | 0.050 |
Why?
|
| Thyroxine | 1 | 2002 | 11 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2017 | 414 | 0.050 |
Why?
|
| Liver Function Tests | 1 | 2002 | 9 | 0.050 |
Why?
|
| Leukocyte Count | 1 | 2002 | 25 | 0.050 |
Why?
|
| Parathyroid Neoplasms | 1 | 2001 | 4 | 0.050 |
Why?
|
| Injections | 1 | 2001 | 31 | 0.050 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2001 | 19 | 0.050 |
Why?
|
| Vitiligo | 1 | 2001 | 6 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2001 | 15 | 0.050 |
Why?
|
| Cloning, Molecular | 1 | 2002 | 205 | 0.050 |
Why?
|
| ADAM17 Protein | 1 | 2021 | 13 | 0.050 |
Why?
|
| Thymocytes | 1 | 2021 | 12 | 0.050 |
Why?
|
| Sepharose | 1 | 2001 | 14 | 0.050 |
Why?
|
| Knee Joint | 2 | 2017 | 43 | 0.050 |
Why?
|
| Cytoplasm | 1 | 2021 | 57 | 0.050 |
Why?
|
| Mice, Inbred NOD | 1 | 2021 | 49 | 0.050 |
Why?
|
| Visual Analog Scale | 1 | 2021 | 6 | 0.050 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2001 | 6 | 0.050 |
Why?
|
| Receptors, Interleukin-1 Type II | 1 | 2021 | 1 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2021 | 1244 | 0.050 |
Why?
|
| Green Fluorescent Proteins | 1 | 2021 | 101 | 0.050 |
Why?
|
| Leucine Zippers | 1 | 2001 | 7 | 0.050 |
Why?
|
| Adoptive Transfer | 1 | 2021 | 25 | 0.040 |
Why?
|
| Disulfides | 1 | 2021 | 33 | 0.040 |
Why?
|
| 3T3 Cells | 1 | 2021 | 46 | 0.040 |
Why?
|
| Germ Cells | 1 | 2021 | 15 | 0.040 |
Why?
|
| Adenoma | 1 | 2001 | 61 | 0.040 |
Why?
|
| Protein Multimerization | 1 | 2021 | 57 | 0.040 |
Why?
|
| RNA-Binding Proteins | 1 | 2021 | 86 | 0.040 |
Why?
|
| Nitric Oxide | 1 | 2021 | 152 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 1 | 2001 | 284 | 0.040 |
Why?
|
| Granulocytes | 1 | 2000 | 6 | 0.040 |
Why?
|
| Binding Sites | 1 | 2001 | 352 | 0.040 |
Why?
|
| Calreticulin | 1 | 2000 | 5 | 0.040 |
Why?
|
| Polymers | 1 | 2021 | 117 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2021 | 192 | 0.040 |
Why?
|
| Computational Biology | 1 | 2021 | 155 | 0.040 |
Why?
|
| Models, Molecular | 1 | 2021 | 452 | 0.040 |
Why?
|
| Gene Expression | 1 | 2021 | 415 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2021 | 507 | 0.040 |
Why?
|
| Depression | 1 | 2021 | 215 | 0.040 |
Why?
|
| Plastics | 1 | 1999 | 6 | 0.040 |
Why?
|
| Macrophages | 1 | 2021 | 292 | 0.040 |
Why?
|
| Autoradiography | 1 | 1998 | 28 | 0.040 |
Why?
|
| Drug Storage | 1 | 1998 | 4 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 1011 | 0.040 |
Why?
|
| Breakfast | 1 | 2017 | 5 | 0.040 |
Why?
|
| Fruit and Vegetable Juices | 1 | 2017 | 5 | 0.040 |
Why?
|
| Freeze Drying | 1 | 2017 | 10 | 0.040 |
Why?
|
| Delayed Diagnosis | 1 | 2017 | 19 | 0.040 |
Why?
|
| Interleukin-18 | 1 | 2017 | 17 | 0.040 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2017 | 4 | 0.040 |
Why?
|
| Adrenergic beta-1 Receptor Agonists | 1 | 2017 | 4 | 0.040 |
Why?
|
| Adrenergic alpha-1 Receptor Agonists | 1 | 2017 | 2 | 0.040 |
Why?
|
| Models, Biological | 2 | 2008 | 466 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2017 | 95 | 0.040 |
Why?
|
| Postprandial Period | 1 | 2017 | 44 | 0.030 |
Why?
|
| Cricetulus | 1 | 2017 | 56 | 0.030 |
Why?
|
| ROC Curve | 1 | 2017 | 143 | 0.030 |
Why?
|
| CHO Cells | 1 | 2017 | 96 | 0.030 |
Why?
|
| Arterioles | 1 | 2017 | 61 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 1998 | 520 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 2017 | 47 | 0.030 |
Why?
|
| Vasoconstriction | 1 | 2017 | 45 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 202 | 0.030 |
Why?
|
| Isotope Labeling | 1 | 1997 | 30 | 0.030 |
Why?
|
| Twins, Monozygotic | 1 | 1997 | 6 | 0.030 |
Why?
|
| Fibrosis | 1 | 2017 | 131 | 0.030 |
Why?
|
| Cariostatic Agents | 1 | 2016 | 4 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2017 | 166 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1997 | 77 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 1996 | 67 | 0.030 |
Why?
|
| Dental Caries | 1 | 2016 | 22 | 0.030 |
Why?
|
| Hydroxychloroquine | 1 | 2016 | 20 | 0.030 |
Why?
|
| Fluorides | 1 | 2016 | 10 | 0.030 |
Why?
|
| Transfection | 1 | 2017 | 317 | 0.030 |
Why?
|
| Graves Disease | 1 | 1996 | 8 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2016 | 50 | 0.030 |
Why?
|
| Hypergammaglobulinemia | 1 | 2016 | 7 | 0.030 |
Why?
|
| Rituximab | 1 | 2016 | 62 | 0.030 |
Why?
|
| Tripartite Motif Proteins | 1 | 2016 | 8 | 0.030 |
Why?
|
| Sulfur Radioisotopes | 1 | 2016 | 10 | 0.030 |
Why?
|
| Self Care | 1 | 2016 | 42 | 0.030 |
Why?
|
| United States Public Health Service | 1 | 1996 | 2 | 0.030 |
Why?
|
| Methionine | 1 | 2016 | 37 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2016 | 54 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2016 | 21 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2017 | 430 | 0.030 |
Why?
|
| Sulfasalazine | 1 | 1995 | 2 | 0.030 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2016 | 70 | 0.030 |
Why?
|
| Spondylitis | 1 | 1995 | 4 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 1995 | 40 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 1995 | 34 | 0.030 |
Why?
|
| Receptors, Complement 3b | 1 | 2014 | 7 | 0.030 |
Why?
|
| Blotting, Southern | 1 | 1994 | 26 | 0.030 |
Why?
|
| Histidine | 1 | 2015 | 52 | 0.030 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1994 | 26 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 1995 | 297 | 0.030 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2014 | 30 | 0.030 |
Why?
|
| Leucine | 1 | 1994 | 20 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2014 | 14 | 0.030 |
Why?
|
| Glutamine | 1 | 1994 | 32 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2014 | 19 | 0.030 |
Why?
|
| Cell Transplantation | 1 | 1994 | 10 | 0.030 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2014 | 50 | 0.030 |
Why?
|
| CpG Islands | 1 | 2014 | 26 | 0.030 |
Why?
|
| Estrogens | 1 | 2014 | 56 | 0.030 |
Why?
|
| Microsatellite Repeats | 2 | 2005 | 56 | 0.030 |
Why?
|
| Amino Acids | 1 | 1994 | 82 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 1993 | 111 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2016 | 657 | 0.030 |
Why?
|
| Antibodies, Anticardiolipin | 1 | 2013 | 23 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2013 | 58 | 0.030 |
Why?
|
| NADH Dehydrogenase | 1 | 2013 | 6 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2013 | 15 | 0.030 |
Why?
|
| Europe | 1 | 2013 | 98 | 0.030 |
Why?
|
| Glutathione Reductase | 1 | 2013 | 17 | 0.030 |
Why?
|
| Electron Transport Complex I | 1 | 2013 | 13 | 0.030 |
Why?
|
| Consensus | 1 | 2013 | 74 | 0.030 |
Why?
|
| Ku Autoantigen | 1 | 2013 | 12 | 0.030 |
Why?
|
| Interferon-Induced Helicase, IFIH1 | 1 | 2013 | 11 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2013 | 34 | 0.030 |
Why?
|
| Seroepidemiologic Studies | 1 | 2012 | 10 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 1993 | 79 | 0.030 |
Why?
|
| Gram-Negative Bacteria | 1 | 1993 | 62 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 2012 | 42 | 0.030 |
Why?
|
| Ribosomal Proteins | 1 | 2012 | 20 | 0.030 |
Why?
|
| Biological Evolution | 1 | 1993 | 99 | 0.030 |
Why?
|
| Genome, Human | 1 | 2013 | 69 | 0.030 |
Why?
|
| Morbidity | 1 | 2012 | 58 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2013 | 246 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2013 | 191 | 0.020 |
Why?
|
| Codon, Initiator | 1 | 2012 | 6 | 0.020 |
Why?
|
| Genes, Recessive | 1 | 2012 | 21 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2012 | 58 | 0.020 |
Why?
|
| Apolipoprotein L1 | 1 | 2011 | 10 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2012 | 103 | 0.020 |
Why?
|
| Genetics, Population | 1 | 2012 | 73 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1991 | 47 | 0.020 |
Why?
|
| Seasons | 1 | 1992 | 87 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2011 | 34 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2012 | 123 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2012 | 248 | 0.020 |
Why?
|
| Tumor Necrosis Factor alpha-Induced Protein 3 | 1 | 2011 | 24 | 0.020 |
Why?
|
| Interferon-alpha | 1 | 2011 | 50 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2011 | 119 | 0.020 |
Why?
|
| Vaccines | 1 | 2011 | 33 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2010 | 44 | 0.020 |
Why?
|
| Chemokine CXCL10 | 1 | 2010 | 22 | 0.020 |
Why?
|
| Incidence | 1 | 1992 | 562 | 0.020 |
Why?
|
| Bronchitis, Chronic | 1 | 2008 | 1 | 0.020 |
Why?
|
| Infant | 1 | 1992 | 987 | 0.020 |
Why?
|
| South Carolina | 1 | 2008 | 8 | 0.020 |
Why?
|
| Antigen-Antibody Complex | 2 | 1999 | 17 | 0.020 |
Why?
|
| Plant Preparations | 1 | 2007 | 5 | 0.020 |
Why?
|
| Powders | 1 | 2007 | 19 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2008 | 271 | 0.020 |
Why?
|
| Lipids | 1 | 2007 | 207 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2009 | 967 | 0.020 |
Why?
|
| Genetic Heterogeneity | 1 | 2004 | 31 | 0.010 |
Why?
|
| Lupus Erythematosus, Discoid | 1 | 2004 | 18 | 0.010 |
Why?
|
| Physical Chromosome Mapping | 1 | 2003 | 8 | 0.010 |
Why?
|
| HLA-DR Antigens | 1 | 2003 | 29 | 0.010 |
Why?
|
| Military Personnel | 1 | 2003 | 47 | 0.010 |
Why?
|
| Synovial Fluid | 1 | 2002 | 12 | 0.010 |
Why?
|
| Models, Animal | 1 | 2002 | 129 | 0.010 |
Why?
|
| Genes | 1 | 2001 | 36 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 2001 | 66 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2001 | 68 | 0.010 |
Why?
|
| Mice, Inbred AKR | 1 | 1999 | 2 | 0.010 |
Why?
|
| Antigen-Presenting Cells | 1 | 1999 | 32 | 0.010 |
Why?
|
| Papio | 1 | 1998 | 79 | 0.010 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 1997 | 21 | 0.010 |
Why?
|
| Endopeptidase K | 1 | 1997 | 4 | 0.010 |
Why?
|
| Chloroform | 1 | 1997 | 4 | 0.010 |
Why?
|
| Bacteriophage T4 | 1 | 1997 | 7 | 0.010 |
Why?
|
| Phosphorylation | 1 | 1997 | 574 | 0.010 |
Why?
|
| Environment | 1 | 1994 | 65 | 0.010 |
Why?
|
| Viral Matrix Proteins | 1 | 1993 | 6 | 0.010 |
Why?
|
| Panama | 1 | 1993 | 20 | 0.010 |
Why?
|
| Computer Simulation | 1 | 1994 | 230 | 0.010 |
Why?
|